IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
Life review of elderly depression
Development and application of ATR-FTIR spectroscopy for mixture homogeneity in pharmaceutical application
The Increasing Damage in Tubular Cell of Infant Mice’s Kidneys from Carbofuran Exposure during its Mothers’ Lactation Period
Trend of transsexualism problem and its implications towards muslim community in Malaysia
Development and validation of RP-HPLC method for the estimation of pidotimod in tablet dosage form
Evaluation of neurotoxicity of the ethanolic bark extract of Holarrhena pubescens Wall. ex G.Don in mice
Design, synthesis and evaluation of 2-aminobenzimidazole derivatives: strong candidate for PPAR gamma agonists.
Prediction of Heart Disease Using Feature Selection and Random Forest Ensemble Method
Strategies for Antiviral Drugs from Plants by Targeting the Hemagglutinin, Neuraminidase and other receptors of Influenza A virus
The impact of human resource and quality management in health care: A Review
12345678910...
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
“Stability Indicating RP-HPLC Method Development and Validation for the Estimation of Remogliflozin Etabonate in Bulk and Pharmaceutical Dosage Form”

Author: TUSHAR BHATKAR, AMOL V. BADKHAL, NITIN S. BHAJIPALE
Abstract: A simple, fast, and highly selective RP-HPLC method was developed for the determination of remogliflozin etabonate in API and tablet dosage form. The separation was done by using Agilent technology HPLC. Column Agilent C18 (250mm × 4.6 mm) with Mobile Phase was Methanol : 0.1% Ortho phosphoric acid (80:20% v/v). The flow rate was 0.9ml/min, and the analytes were measured at ?max 227 nm. The retention time for remogliflozin etabonate was 4.881 min, respectively. The method was validated with respect to system suitability, linearity, precision, accuracy, specificity, limit of detection (LOD), limit of quantification (LOQ), robustness and ruggedness. Linearity studies was performed (10–60µg/ml), LOD and LOQ was found to be 0.2201 and 0.6669 µg/ml respectively. The relative standard deviation for accuracy was found to be less than 2 %. The mean percentage recovery was 99.50% to 100.12 %.The forced degradation studies were carried out by using 0.01N NaOH, 1.0 N HCl, 3 % H2O2. Deprivation performance shows that the major deprivation was observed at basic condition i.e. NaOH (5.06 %) followed by HCl (4.71%), H2O2 (4.04%) and Thermal (5.45) respectively.
Keyword: Remogliflozin etabonate, Methanol, RP-HPLC, Method development, Validation, Forced degradation.
DOI: https://doi.org/10.31838/ijpr/2020.12.04.026
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free